Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis
Research paperCyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks☆
References (299)
- et al.
Induction by indirect mutagens/carcinogens, aryl hydrocarbon hydroxylase activity and benzo[a]pyrene metabolism in cultured human hepatoma cells
Mutation Res.
(1983) ICPEM Working Paper 4/3: Comparison of types of chemically induced genetic changes in mammals
Mutation Res.
(1983)Reevaluation of the 9 compounds reported conclusive positive in yeast Saccharomyces cerevisiae aneuploidy test systems by the Gene-Tox program using strain D61.M of Saccharomyces cerevisiae
Mutation Res.
(1991)- et al.
Synaptonemal complex damage as a measure of chemical mutagen effects on mammalian germ cells
Mutation Res.
(1987) - et al.
Elevated frequencies of 6-thioguanine-resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: a prospective study
Mutation Res.
(1988) - et al.
Cyclophosphamide in the F0 male rat: physical and behavorial changes in three successive adult generations
Mutation Res.
(1990) - et al.
Synaptonemal complex damage in relation to meiotic chromosome aberrations after exposure of male mice to cyclophosphamide
Mutation Res.
(1988) - et al.
Expression of genetic damage induced by alkylating agents in germ cells of female mice
Mutation Res.
(1982) - et al.
Detection of micronuclei after exposure to mitomycin C, cyclophosphamide and diethylnitrosamine by the in vivo micronucleus test in mouse splenocytes
Mutation Res.
(1992) - et al.
N-(2-major hydroxyethyl)-N-[2-(7-guaninyl)ethyl]amine, the putative DNA adduct of cyclophosphamide in vitro and in vivo in the rat
Biochem. Pharmacol.
(1988)
Activity of germ-cell mutagens and nonmutagens in the rat spermatocyte UDS assay
Mutation Res.
The effect of chemotherapy on the in vivo frequency of glycophorin A ‘null’ variant erythrocytes
Mutation Res.
Cytogenetic effects of cyclophosphamide on human lymphocytes in vivo and in vitro
Mutation Res.
Cyclophosphamide-associated carcinoma of urothelium: modalities for prevention
Urology
The role of individual cytochromes P450 in drug metabolism and clinical response
Trends Pharmacol. Sci.
Cytogenetic effects of diethylstilbestrol-diphosphate (Des-dp) on mouse bone marrow monitored by the micronucleus test
Mutation Res.
Micronuclei in bone-marrow cells of mice subjected to hyperthermia
Mutation Res.
Short-term tests for transplacentally active carcinogens. A comparison of sister-chromatid exchange and the micronucleus test in mouse foetal liver crythroblasts
Mutation Res.
Cyclophosphamide cystitis — identification of acrolein as the causative agent
Biochem. Pharmacol.
Evaluation of a human hepatoma cell line as a target cell in genetic toxicology
Mutation Res.
In vitro assays of in vivo exposure to cyclophosphamide: Induction of sister-chromatid exchanges in peripheral lymphocytes, bone-marrow cells and in cultured cells exposed to plasma
Mutation Res.
Mutagenicity tests with nickel salts in the male mouse
Toxicol.
Influence of various mitogens on the yield of sister-chromatid exchanges, induced by chemicals, in human lymphocytes
Mutation Res.
Decreased half-life of cyclophosphamide in patients under continual treatment
Eur. J. Cancer
Induction of specific-locus and dominant-lethal mutations by cyclophosphamide and combined cyclophosphamide-radiation treatments
Mutation Res.
Dominant cataract mutations and specific locus mutations in mice induced by radiation or ethylnitrosourea
Mutation Res.
Detection of chemical mutagens by the dominant lethal assay in the mouse
Toxicol. Appl. Pharmacol.
Postmeiotic cell mediation of behaviour in progeny of male rats treated with cyclophosphamide
Mutation Res.
The incidence of bladder cancer after cyclophosphamide therapy
J. Urol.
Enantiomers of cyclophosphamide amd iphosphamide
Biochem. Pharmacol.
Tumours and malformations in the adult offspring of cyclophosphamide-treated and control male rats — Preliminary communication
Mutation Res.
Sister chromatid exchanges induced by cyclophosphamide in V79 cells cultured in difusion chambers in mice
Mutation Res.
Modifications in the myeloclastogenic effect of benzene in mice with toluene, phenobarbital, 3-methylcholanthrene, Aroclor 1254 and SKF-525A
Mutation Res.
The action of anticlastogens in human lymphocyte cultures and their modification by rat-liver S9 mix
Mutation Res.
Relationship between experimental results in mammals and man. I. Cytogenetic analysis of bone marrow injury induced by a single dose of CO
Mutation Res.
Comparison of the effects of 1,2-dimethylhydrazine and cyclophosphamide on micronucleus incidence in bone marrow and colon
Mutation Res.
Thirty compounds tested in the Drosophila wing spot test
Mutation Res.
Drug metabolism in carcinogenesis and cancer chemotherapy
Pharmac. Ther.
Activation of cyclophosphamide using perfused rat liver system and induction of sister chromatid exchanges in vitro
Hum Genet.
Mammalian male germ cell cytogenetics
Mutagenesis
Induction and transmission of chemically induced chromosome aberrations in female germ cells
Environ. Mol. Mutagen.
Bladder cancer in a young girl with systemic lupus erythematous treated with cyclophosphamide
Acta Urol. Belg.
In vivo BrdU-33258 Hoechst analysis of DNA replication kinetics and sister chromatid exchange formation in mouse somatic and meiotic cells
Chromosoma
Synaptonemal complex damage as a measure of genotoxicity at meiosis
Cell Biol. Toxicol.
Vinyl chloride: dominant lethal studies in male CD-1 mice
Mutation Res.
Testing of ethylene oxide for mutagenicity using the micronucleus test in mice and rats
Acta Pharmacol. Toxicol.
Chromosome damage in murine and human cells following cytoxan therapy
Tex. Rep. Biol. Med.
The uptake and metabolism of cyclophosphamide by the ovary
Select. Cancer Ther.
Short-term cytogenetic assays of nine cancer chemotherapeutic drugs with metabolic activation
Environ. Mutagen.
Clinical pharmacology of cyclophosphamide
Cancer Res.
Cited by (268)
Protective effect of polysaccharides from Ostrea rivularis against reproductive injury via regulating autophagy induced by oxidative stress
2022, International Journal of Biological MacromoleculesCytotoxic responses of the anticancer drug cyclophosphamide in the mussel Mytilus galloprovincialis and comparative sensitivity with human cells lines
2020, ChemosphereCitation Excerpt :In humans, CP activation occurs mostly in the liver (Weber and Waxman, 1993) and the resulting metabolites are delivered to neoplastic cells via the bloodstream (Graham et al., 1991). The first step is oxidation of the oxazaphosphorine ring by cytochrome P-450 oxidases to form the unstable intermediate 4-hydroxy-CP (4-OHCP) which coexists with its tautomer, aldophosphamide (Anderson et al., 1995; Hales, 1982). This unstable transport precursor freely diffuses into the cells, where they undergo spontaneous β-deletion and give rise to acrolein and phosphoramide mustard, respectively responsible for producing high levels of oxidative stress and DNA crosslinks (Emadi et al., 2009; Tripathi etal, 2009).
Genotoxic potential of a novel PDE-4B inhibitor Apremilast by chromosomal aberration and micronucleus assay in mice
2020, Saudi Pharmaceutical JournalCitation Excerpt :However, it is also known as a carcinogen and produce tumors in human (Alshahrani et al., 2019). It is also associated with chromosome aberrations, genetic mutations, sister chromatid and micronuclei exchanges (Anderson et al., 1995). In our study, cyclophosphamide at a dose of 40 mg/kg shows genotoxic effect significantly (p < 0.001) in comparison to normal control animals which indicate chromosomal aberrations were successfully induced in disease control animals.
Paternal safety of anti-rheumatic medications
2020, Best Practice and Research: Clinical Obstetrics and GynaecologyAssessment of metronomic chemotherapy–induced DNA damage in peripheral blood leukocytes from canine mammary cancer patients using the alkaline comet assay
2024, Revista Cientifica de la Facultad de Veterinaria
- ☆
The authors are members of the Working Group on Cyclophosphamide assembled for the EC/Us Workshop on Risk Assessment. This Working Group wishes to extend its special appreciation to Drs. M.N. Routledge and I.R. McConnell for their assistance in preparation of the ‘Chemistry, Pharmacokinetics and Metabolism’ and ‘DNA Adducts’, and Dr. Regina Montero for assistance in preparation of the ‘Mammalian Somatic Cells’ sections of this paper.